Invited review: Neuroprotective properties of certain β-adrenoceptor antagonists used for the treatment of glaucoma

Journal of Ocular Pharmacology and Therapeutics

Volumn 21, Issue 3, 2005, Pages 175-181

  Osborne, Neville N ^a   Wood, John P M ^a   Chidlow, Glyn ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CARTEOLOL; CARVEDILOL; CATALASE; DIZOCILPINE; DORZOLAMIDE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; GLUTATHIONE PEROXIDASE; LATANOPROST; LEVOBETAXOLOL; LEVOBUNOLOL; MEMANTINE; METIPRANOLOL; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PILOCARPINE; PROPRANOLOL DERIVATIVE; REACTIVE OXYGEN METABOLITE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; SODIUM ION; SUPEROXIDE DISMUTASE; TIMOLOL; TRAVOPROST; TROLOX C; UNCLASSIFIED DRUG; UNIPROSTONE; VERATRIDINE;

ANTIOXIDANT ACTIVITY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL DEATH; DISEASE CLASSIFICATION; DRUG ACTIVITY; GLAUCOMA; INTRAOCULAR PRESSURE; ISCHEMIA; LOW TENSION GLAUCOMA; NERVE CELL NECROSIS; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; PATHOGENESIS; PERIKARYON; REVIEW; SODIUM CELL LEVEL; SODIUM TRANSPORT;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; GLAUCOMA; HUMANS; NEUROPROTECTIVE AGENTS; RETINAL GANGLION CELLS;

EID: 21644470695     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2005.21.175     Document Type: Review

References (50)

1. Osborne, N.N., Melena, J., Chidlow, G., and Wood, J.P. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br. J. Ophthalmol. 85:1252-1259, 2001.
2. Morgan, J.E. Optic nerve head structure in glaucoma: astrocytes as mediators of axonal damage. Eye 14:437-444, 2000.
3. Woodward, D.F., and Gil, D.W. The inflow and outflow of anti-glaucoma drugs. Trends Pharmacol. Sci. 25:238-241, 2004.
4. Osborne, N.N., De Santis, L.M., Bae, J.H., Ugarte, M., Wood, J.P.M., Nash, M.S., and Chidlow, G. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp. Eye Res. 69:331-342, 1999.
5. Acheampong, A.A., Shackleton, M., John, B., Burke, J., Wheeler, L., and Tang Liu, D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 30:421-429, 2002.
6. Tan, A.Y., LeVatte, T.L., Archibald, M.L., Tremblay, F., Kelly, M.E., and Chauhan, B.C. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing. J. Glaucoma 11:134-142, 2002.
7. Frishman, W.H., Fuksbrumer, M.S., and Tannenbaum, M. Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J. Clin. Pharmacol. 34:795-803, 1994.
8. Hoyng, P.P., and van Beek, L.M. Pharmacological therapy for glaucoma: a review. Drugs 59:411-434, 2000.
9. Wood, J.P., DeSantis, L., Chao, H.M., and Osborne, N.N. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp. Eye Res. 72:79-86, 2001.
10. Cheon, E.W., Kim, Y.H., Cho, Y.Y., Kim, H.J., Kang, S.S., Cho, G.J., Yoo, J.M., Song, J.K., and Choi, W.S. Betaxolol, a beta1-adrenoceptor antagonist, protects a transient ischemic injury of the retina. Exp. Eye Res. 75:591-601, 2002.
11. Wood, J.P., Schmidt, K.G., Melena, J., Chidlow, G., Allmeier, H., and Osborne, N.N. The beta-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp. Eye Res. 76:505-516, 2003.
12. Cheon, E.W., Park, C.H., Kang, S.S., Cho, G.J., Yoo, J.M., Song, J.K., and Choi, W.S. Betaxolol attenuates retinal ischemia/reperfusion damage in the rat. Neuroreport 14:1913-1917, 2003.
13. Fern, R., and Ransom, B.R. Ischemic injury of optic nerve axons: the nuts and bolts. Clin. Neurosci. 4:246-250, 1997.
14. Stys, P.K. White matter injury mechanisms. Curr. Mol. Med. 4:113-130, 2004.
15. Chiu, S.Y., Zhou, L., Zhang, C.L., and Messing, A. Analysis of potassium channel functions in mammalian axons by gene knockouts. J. Neurocytol. 28:349-364, 1999.
16. + channels: electrifying regulators of synaptic terminal excitability. Trends Neurosci. 27:210-217, 2004.
17. Stys, P.K., Ransom, B.R., and Waxman, S.G. Tertiary and quaternary local anesthetics protect CNS white matter from anoxic injury at concentrations that do not block excitability. J. Neurophysiol. 67:236-240, 1992.
18. Chidlow, G., Melena, J., and Osborne, N.N. Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. Br. J. Pharmacol. 130:759-766, 2000.
19. Osborne, N.N., Wood, J.P., Chidlow, G., Casson, R., DeSantis, L., and Schmidt, K.G. Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma. Brain Res. Bull. 62:525-528, 2004.
20. Gross, R.L., Hensley, S.H., and Wu, S.M. Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of β-blockers. Surv. Ophthalmol. 43:5162-5170, 1999.
21. Hirooka, K., Kelly, M.E., Baldridge, W.H., and Barnes, S. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp. Eye Res. 70:611-621, 2000.
22. Netland, P.A., Chaturvedi, N., and Dreyer, E.B. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am. J. Ophthalmol. 115:608-613, 1993.
23. Daugeliene, L., Yamamoto, T., and Kitazawa, Y. Risk factors for visual field damage progression in normal-tension glaucoma eyes. Graefes Arch. Clin. Exp. Ophthalmol. 237:105-108, 1999.
24. Boehm, A.G., Breidenbach, K.A., Pillunat, L.E., Bernd, A.S., Mueller, MF., and Koeller, A.U. Visual function and perfusion of the optic nerve head after application of centrally acting calcium-channel blockers. Graefes Arch. Clin. Exp. Ophthalmol. 241:34-38, 2003.
25. Lipton, P. Ischemic cell death in brain neurons. Physiol. Rev. 79:1431-1568, 1999.
26. Osborne, N.N., Ugarte, M., Chao, M., Chidlow, G., Bae, J.H., Wood, J.P., and Nash, M.S. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv. Ophthalmol. 43(Suppl 1):S102-S128, 1999.
27. Osborne, N.N., Casson, R.J., Wood, J.P., Chidlow, G., Graham, M., and Melena, J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res. 23:91-147, 2004.
28. Dreyer, E.B., Zurakowski, D., Schumer, R.A., Podos, S.M., and Lipton, S.A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 114:299-305, 1996.
29. Yoles, E., and Schwartz, M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch. Ophthalmol. 116:906-910, 1998.
30. Osborne, N.N. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis. Neurosci. 16:45-52, 1999.
31. Lam, T.T., Siew, E., Chu, R., and Tso, M.O. Ameliorative effect of MK-801 on retinal ischemia. J. Ocul. Pharmacol. Ther. 13:129-137, 1997.
32. Chaudhary, P., Ahmed, F., and Sharma, S.C. MK801-a neuroprotectant in rat hypertensive eyes. Brain Res. 792:154-158, 1998.
33. Crosson, C.E., Willis, J.A., and Potter, D.E. Effect of the calcium antagonist, nifedipine, on ischemic retinal dysfunction. J. Ocul. Pharmacol. 6:293-299, 1990.
34. Osborne, N.N., Wood, J.P., Cupido, A., Melena, J., and Chidlow, G. Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity. Invest. Ophthalmol. Vis. Sci. 43:1456-1464, 2002.
35. Toriu, N., Akaike, A., Yasuyoshi, H., Zhang, S., Kashii, S., Honda, Y., Shimazawa, M., and Hara, H. Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp. Eye Res. 70:475-484, 2000.
36. Ettaiche, M., Fillacier, K., Widmann, C., Heurteaux, C., and Lazdunski, M. Riluzole improves functional recovery after ischemia in the rat retina. Invest. Ophthalmol. Vis. Sci. 40:729-736, 1999.
37. Yoneda, S., Tanaka, E., Goto, W., Ota, T., and Hara, H. Topiramate reduces excitotoxic and ischemic injury in the rat retina. Brain Res. 967:257-266, 2003.
38. Hoste, A.M., and Sys, S.U. Ca2+ channel-blocking activity of propranolol and betaxolol in isolated bovine retinal microartery. J. Cardiovasc. Pharmacol. 32:390-396, 1998.
39. Yu, D.Y., Su, E.N., Cringle, S.J., Alder, V.A., Yu, P.K., and DeSantis, L. Systemic and ocular vascular roles of the antiglaucoma agents beta-adrenergic antagonists and Ca2+ entry blockers. Surv. Ophthalmol. 43(Suppl 1):S214-S222, 1999.
40. 2+ channels. Eur. J. Pharmacol. 378:317-322, 1999.
41. Melena, J., Stanton, D., and Osborne, N.N. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch. Clin. Exp. Ophthalmol. 239:522-530, 2001.
42. Andersen, J.K. Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 10(Suppl):S18-S25, 2004.
43. Langley, B., and Ratan, R.R. Oxidative stress-induced death in the nervous system: cell cycle dependent or independent? J. Neurosci. Res. 77:621-629, 2004.
44. Turrens, J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 552:335-344, 2003.
45. Neufeld, A.H., Kawai, S., Das, S., Vora, S., Gachie, E., Connor, J.R., and Manning, P.T. Loss of retinal ganglion cells following retinal ischemia: the role of inducible nitric oxide synthase. Exp. Eye Res. 75:521-528, 2002.
46. Yue, T.L., Cheng, H.Y., Lysko, P.G., McKenna, P.J., Feuerstein, R., Gu, J.L., Lysko, K.A., Davis, L.L., and Feuerstein, G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263:92-98, 1992.
47. Miura, T., Muraoka, S., and Fujimoto, Y. Inhibition of lipid peroxidation by pindolol. Pharmacol. Toxicol. 84:130-134, 1999.
48. Weglicki, W.B., Mak, I.T., and Simic, M.G. Mechanisms of cardiovascular drugs as antioxidants. J. Mol. Cell. Cardiol. 22:1199-1208, 1990.
49. Melena, J., and Osborne, N.N. Metipranolol attenuates lipid peroxidation in rat brain: a comparative study with other antiglaucoma drugs. Graefes Arch. Clin. Exp. Ophthalmol. 241:827-833, 2003.
50. Osborne, N.N., and Wood, J.P. Metipranolol blunts nitric oxide-induced lipid peroxidation and death of retinal photoreceptors: a comparison with other anti-glaucoma drugs. Invest. Ophthalmol. Vis. Sci. 45: 3787-3795, 2004.